Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CG001419 in Advanced Solid Tumors with NTRK Alterations
NCT07394374Phase 2Recruiting
- Sponsor
- Cullgen Inc.
- Start
- Jun 2023
- Primary completion
- Aug 2030
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
A Phase 2 trial of CG001419 in solid tumor, sponsored by Cullgen Inc.. Started Jun 2023; status: recruiting.
02
Drugs
CG001419
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07394374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07394374.